Skip to main content

Table 2 Changes in inflammatory cytokines and oxidative stress after the intensive insulin therapy in T2DM patients (x ± s)

From: Effect of rosiglitazone on inflammatory cytokines and oxidative stress after intensive insulin therapy in patients with newly diagnosed type 2 diabetes

  Rosiglitazone Metformin Rosiglitazone plus metformin Insulin aspart 30
Baseline 48 weeks Baseline 48 weeks Baseline 48 weeks Baseline 48 weeks
TNFα (pg/mL) 28.57 ± 10.37 22.12 ± 11.66* 30.24 ± 15.78 28.33 ± 12.34 27.91 ± 12.21 21.59 ± 9.82* 28.75 ± 13.84 27.87 ± 10.22
IL-6 (pg/mL) 8.13 ± 2.22 6.68 ± 3.69* 9.21 ± 3.12 8.79.45 ± 4.01 8.88 ± 3.91 5.13 ± 3.93*a 8.29 ± 4.63 7.31 ± 4.35
Il-1β (ng/mL) 3.65 ± 1.63 3.71 ± 1.98 3.93 ± 2.95 3.52 ± 2.07 3.78 ± 2.26 4.02 ± 1.99 3.65 ± 2.62 4.83 ± 1.59
hs-CRP (mg/L) 4.45 ± 1.51 3.24 ± 1.96* 4.90 ± 1.98 3.01 ± 1.77* 4.86 ± 1.70 2.23 ± 1.57*a 4.67 ± 1.37 4.11 ± 1.18
SOD (kU/L) 72.62 ± 18.56 76.36 ± 20.26* 76.32 ± 20.21 80.55 ± 25.27 74.98 ± 19.50 79.24 ± 23.70a 75.46 ± 21.56 78.68 ± 22.33
MDA (μmol/L) 6.03 ± 1.42 4.28 ± 1.94* 6.94 ± 1.68 5.22 ± 1.73* 6.53 ± 1.25 4.98 ± 1.56* 6.14 ± 1.88 4.38 ± 1.62*
8-iso-PGF (μg/L) 10.35 ± 4.44 8.87 ± 5.91* 12.11 ± 7.66 7.65 ± 7.15* 11.30 ± 6.80 7.22 ± 6.31*a 10.87 ± 6.83 8.94 ± 6.34*
TAC (kU/L) 24.62 ± 10.69 27.30 ± 12.35* 25.31 ± 12.24 28.97 ± 9.18* 23.66 ± 11.01 27.00 ± 10.82* 24.48 ± 12.47 28.83 ± 10.82*
  1. P < 0.05, compared with the baseline level
  2. P < 0.01, compared with the baseline level
  3. aP < 0.05, compared with the RSG group after treatment